Search Results - "Rouas, G"

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites by Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., Larsimont, D.

“…Background: The humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin®) is a new treatment modality for metastatic breast cancer, the efficacy of…”
Get full text

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab by Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., Sotiriou, C.

“…Immune checkpoint blockade (ICB) in combination with chemotherapy improves outcome of patients with triple-negative breast cancer (TNBC) in metastatic and…”
Get full text

Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes by Martin Martinez, M.D, Veys, I, Majjaj, S, Lespagnard, L, Schobbens, J.C, Rouas, G, Filippov, V, Noterman, D, Hertens, D, Feoli, F, Bourgeois, P, Durbecq, V, Larsimont, D, Nogaret, J.M

“…Abstract Background In breast cancer patients, the status of the sentinel lymph nodes (SLNs) has been shown to accurately reflect the presence of metastases in…”
Get full text

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer by Cardoso, F, Durbecq, V, Larsimont, D, Paesmans, M, Leroy, J Y, Rouas, G, Sotiriou, C, Renard, N, Richard, V, Piccart, M J, Di Leo, A

“…Anthracycline-based regimens are among the most active but also with greater risk of both acute and long-term side effects, namely cardiotoxicity. Predictive…”
Get more information

Evaluation of HER2, p53, bcl-2, topoisomerase II-α, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes by Cardoso, F., Leo, A. Di, Larsimont, D., Gancberg, D., Rouas, G., Dolci, S., Ferreira, F., Paesmans, M., Piccart, M.

“…Background: Breast cancer is a heterogeneous disease. Predictive biological markers (BM) of responsiveness to therapy need to be identified. Evaluation of BM…”
Get full text

HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide by Di Leo, A., Larsimont, D., Gabcberg, D., Jarvinen, T., Beauduin, M., Vindevoghel, A., Michel, J., Focan, Ch, Ries, F., Gobert, Ph, Closon-Dejardin, M.-T., Dolci, S., Rouas, G., Paesmans, M., Lobelle, J.-P., Isola, J., Piccart, M. J.

“…Background: The predictive role of HER-2 in node-positive breast cancer patients receiving CMF or an anthracycline-based adjuvant therapy remains unclear. In…”
Get full text

Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer by Durbecq, V, Desmed, C, Paesmans, M, Cardoso, F, Di Leo, A, Mano, M, Rouas, G, Leroy, J-Y, Sotiriou, C, Piccart, M, Larsimont, D

“…Topoisomerase-IIalpha (topo-II) is a molecular target for topo-II inhibitors, which makes it a potential predictive marker of responsiveness to these agents…”
Get more information

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases by GANCBERG, D, LESPAGNARD, L, ROUAS, G, PAESMANS, M, PICCART, M, DI LEO, A, NOGARET, J.-M, HERTENS, D, VERHEST, A, LARSIMONT, D

“…Overexpression and amplification of the HER-2 oncogene in patients with breast cancer has correlated with early onset of metastasis, resistance to hormonal…”
Get full text

Comparison of topoisomerase-IIα gene status between primary breast cancer and corresponding distant metastatic sites by DURBECQ, V, DI LEO, A, CARDOSO, F, ROUAS, G, LEROY, J. Y, PICCART, M, LARSIMONT, D

Get full text

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma by Gancberg, D, Di Leo, A, Rouas, G, Järvinen, T, Verhest, A, Isola, J, Piccart, M J, Larsimont, D

“…Aims: Tumour tissue microarray allows the analysis of hundreds of tumour samples simultaneously on a single microscope slide. However, the extremely small…”
Get full text

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients by Haibe-Kains, B., Desmedt, C., Di Leo, A., Azambuja, E., Larsimont, D., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.P., Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G., Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R., Bontempi, G., Michiels, S., Buyse, M., Nogaret, J.M., Qi, Y., Symmans, F., Pusztai, L., D'Hondt, V., Piccart-Gebhart, M., Sotiriou, C.

“…Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP)…”
Get full text

Expression of p53 in preneoplastic and early neoplastic bronchial lesions by Martin, B, Verdebout, J-M, Mascaux, C, Paesmans, M, Rouas, G, Verhest, A, Ninane, V, Sculier, J-P

“…p53 alteration has been reported to be an early event in bronchial carcinogenesis. Our study purpose was to determine the rate of p53 expression in the various…”
Get more information

1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications by Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Gacquer, D., Dupont, F., Rouas, G., Serra, M., Lundeberg, J., Rothé, F., Sotiriou, C.

Get full text

Integrating spatial and single cell transcriptomics to identify and characterize biologically driven subgroups in invasive lobular carcinoma by Serra, M., Papagiannis, A., Rediti, M., Lifrange, F., Occelli, N., Collet, L., Vincent, D., Rouas, G., Fimereli, D., Craciun, L., Larsimont, D., Venet, D., Duhoux, F., Vikkula, M., Rothé, F., Sotiriou, C.

Get full text

Unravelling tumor heterogeneity in patients with HER2-low hormone receptor-positive breast cancer using spatial transcriptomics by Fimereli, D., Serra, M., Rediti, M., Lifrange, F., Occelli, N., Collet, L., Vincent, D., Rouas, G., Craciun, L., Larsimont, D., Venet, D., Vikkula, M., Duhoux, F.P., Rothé, F., Sotiriou, C.

Get full text

Trisomy 6 in Merkel cell carcinoma: a recurrent chromosomal aberration by Gancberg, D, Feoli, F, Hamels, J, De Saint-Aubain, N, André, J, Rouas, G, Verhest, A, Larsimont, D

“…We retrospectively investigated 17 cases of primary and metastasizing Merkel cell carcinomas (MCC) from 14 patients using chromosomal in‐situ hybridization…”
Get full text

165P Immune characterization of the de novo oligometastatic breast cancer by Chretien, S., Buisseret, L., Wang, X., Rouas, G., Kotecki, N., Garaud, S., Mailliez, A., Larsimont, D., Rothé, F., Sotiriou, C.

Get full text

1726P Investigating adipocytes-tumor cells interaction and its effect on disease progression in lobular breast cancer with spatial transcriptomics by Serra, M., Collet, L., Rediti, M., Lifrange, F., Venet, D., Occelli, N., Vincent, D., Rouas, G., Larsimont, D., Craciun, L., Wang, X., Gacquer, D., Vikkula, M., Duhoux, F.P., Rothé, F., Sotiriou, C.

Get full text

43P Deciphering spatial expression of trop-2, HER2, and AR: Towards customized treatments in triple-negative breast cancer by Carausu, M., Lifrange, F., Venet, D., Rouas, G., Wang, X., Larsimont, D., Rothé, F., Sotiriou, C.

Get full text

Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen by Journe, F, Durbecq, V, Haibe-Kains, B, Chaboteaux, C, Rouas, G, Laurent, G, Larsimont, D, Piccart, M, Body, J.J, Sotiriou, C

Get full text